TargetBeta
CFB
complement factor B · also H2-Bf, BFD, BF · Serine proteases
8 programs in company-led studies act on CFB, from 7 companies: 5 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| iptacopanrule | Novartis | phase 3 | 2512 running | – | ChEMBL |
| NTQ5082rule | Sino Biopharmaceutical | phase 3 | 66 running | – | the studies' text |
| FXS6837 | Fosun Pharma | phase 3 | 44 running | – | the company's pipeline |
| HRS-5965 | Jiangsu HengRui Medicine | phase 3 | 143 running | – | the company's pipeline |
| sefaxersen | Hoffmann-La Roche | phase 3 | 11 running | – | a judged reading |
| HS-10542 | Hansoh Pharmaceutical Group | phase 2 | 33 running | – | the company's pipeline |
| FWY003 | Novartis | phase 2 | 11 running | – | the company's pipeline |
| SAR446597 | Sanofi | phase 2 | 11 running | C1S | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Glomerulonephritis, IGA, 5 programs
- Hemoglobinuria, Paroxysmal, 5 programs
- Geographic Atrophy, 2 programs
- Anemia, Hemolytic, 1 program
- Atypical Hemolytic Uremic Syndrome, 1 program
- Glomerulonephritis, 1 program
- Macular Degeneration, 1 program
- Proteinuria, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026NTQ5082 · Sino Biopharmaceutical · phase 3 · NCT07177859
- Dec 30, 2026iptacopan · Novartis · phase 3 · NCT06388941
- May 30, 2027HS-10542 · Hansoh Pharmaceutical Group · phase 2 · NCT07470762
- Sep 12, 2027FXS6837 · Fosun Pharma · phase 3 · NCT07502638
- Oct 2027HRS-5965 · Jiangsu HengRui Medicine · phase 3 · NCT07014826
- Oct 13, 2027SAR446597 · Sanofi · phase 2 · NCT07215234
- May 25, 2028sefaxersen · Hoffmann-La Roche · phase 3 · NCT05797610
- Aug 21, 2029FWY003 · Novartis · phase 2 · NCT07441642
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.